frontiers in Pharmacology

CORRECTION
published: 18 November 2021
doi: 10.3389/fphar.2021.789192

Corrigendum: ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway

Yu-Li Shen[1,2†], Yi-ping Jiang[3†], Xiao-Qin Li[1,4†], Su-Juan Wang[5], Ming-Hua Ma[6], Chun-Yan Zhang[7], Jian-Yong Zhu[7], Khalid Rahman[8], Li-Jun Zhang[1], Xin Luan[1,2]* and Hong Zhang[1]**

[1]Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China, [2]Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, [3]Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai, China, [4]School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China, [5]Department of Drug Preparation, Hospital of TCM and Hui Nationality Medicine, Ningxia Medical University, Wuzhong, China, [6]Department of Pharmacy, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China, [7]Central Laboratory, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, [8]School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool, United Kingdom*

Keywords: erhuang formula, renal fibrosis, diabetic nephropathy, mechanism, JAK/STAT3

OPEN ACCESS

Edited and reviewed by:
Adolfo Andrade-Cetto, National Autonomous University of Mexico, Mexico

***Correspondence:**
Li-Jun Zhang
zhanglijun0407@163.com,
Xin Luan
luanxin@shutcm.edu.cn,
Hong Zhang
hqzhang51@126.com

†These authors have contributed equally to this work

Specialty section:
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Received: *22 October 2021*
Accepted: *29 October 2021*
Published: *18 November 2021*

Citation:
Shen Y-L, Jiang Y-p, Li X-Q, Wang S-J, Ma M-H, Zhang C-Y, Zhu J-Y, Rahman K, Zhang L-J, Luan X and Zhang H (2021) Corrigendum: ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway. Front. Pharmacol. 12:789192. doi: 10.3389/fphar.2021.789192

A Corrigendum on

ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway

by Shen, Y-L., Jiang, Y-P., Li X-Q., Wang, S-J., Ma, M-H., Zhang, C-Y., Zhu, J-Y., Rahman, K., Zhang, L-J., Luan, X., and Zhang, H. (2020). Front. Pharmacol. 10:1596. doi: 10.3389/fphar.2019.01596

In the original article, there was a mistake during production in **Figure 4** as published. **Figure 4** is identical to **Figure 3.** The corrected **Figure 4** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



FIGURE 4 | EHF inhibited the proliferation of NRK-49F cells and decreased the expression of CXCL6 and CXCR1. **(A)** CCK8 analysis of NRK-49F cell proliferation. **(B)**, **(D)** The mRNA and protein expressions of CXCL6 and CXCR1 in different EHF dose groups were examined by qRT-PCR and Western blotting. GAPDH was served as a loading control. **(C)**, **(E)** The effect of 0.5 mg/ml EHF on the expression of CXCL6 and CXCR1 in CXCL6 overexpression NRK-49F cells was evaluated by qRT-PCR and Western blotting. *p < 0.05, **p < 0.01, ***p < 0.001 versus control group.